FDA Recalls Blood Pressure Medication: Full List of Lots Included in Chlorthalidone Recall

Over 11,000 bottles of Chlorthalidone Tablets USP, 25 mg, a widely prescribed blood pressure medication, have been recalled by India-based manufacturer Inventia Healthcare Limited due to concerns that the pills may not dissolve properly in patients' bodies. This voluntary recall, distributed in the U.S. by Rising Pharma Holdings Inc. and initiated on June 5, 2026, stems from a 'failed dissolution specifications' test, meaning the active ingredient might not be absorbed as intended, potentially rendering the medication ineffective. This isn't just about a faulty pill; it's about the very real risk to patients managing serious cardiovascular conditions. Chlorthalidone is a crucial diuretic used to treat hypertension and fluid retention associated with conditions like heart, kidney, or liver disease. An ineffective dose could lead to uncontrolled high blood pressure or worsening fluid retention, dramatically increasing the risk of life-threatening events like heart attack and stroke. This incident follows a similar recall in May 2026 for Amlodipine and Olmesartan Medoxomil Tablets, also due to dissolution failures, highlighting a worrying trend in pharmaceutical manufacturing quality control. Patients currently using Chlorthalidone Tablets from the affected lot numbers (RISA24001 and RISB24002, expiring April 2027) are strongly advised to contact their healthcare provider or pharmacist before discontinuing or altering their medication. The U.S. Food and Drug Administration (FDA) has documented the recall but, as of now, has not assigned a formal risk classification (like Class I or II) or issued a public press release for this specific event. This ongoing situation underscores the critical need for vigilance in drug quality and patient safety, especially for essential medications.